CoreCap Advisors LLC Raises Stake in Gilead Sciences, Inc. $GILD

CoreCap Advisors LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,624 shares of the biopharmaceutical company’s stock after acquiring an additional 5,039 shares during the period. CoreCap Advisors LLC’s holdings in Gilead Sciences were worth $5,890,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $26,000. Wealth Preservation Advisors LLC increased its holdings in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 82,000 shares of company stock worth $10,641,790 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.80 billion, above the approximately $7.40 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by double-digit HIV growth and continued momentum in Trodelvy. Gilead Q2 Earnings Beat on HIV and Trodelvy Growth
• Positive Sentiment: Management raised its HIV growth outlook to 9%-10% and lifted its 2026 base-business sales outlook to approximately $29.8 billion-$30.1 billion. Yeztugo, Gilead’s HIV PrEP treatment, generated roughly $1 billion in sales as uptake accelerated. Gilead Raises HIV Growth Outlook
• Positive Sentiment: Needham reaffirmed its Buy rating with a $170 price target, while Cantor Fitzgerald maintained Overweight and a $155 target, indicating potential upside if HIV and oncology growth continues.
• Positive Sentiment: Gilead declared its quarterly dividend of $0.82 per share, supporting the stock’s income appeal. The dividend is payable September 29 to shareholders of record September 15.
• Neutral Sentiment: Gilead’s full-year EPS outlook improved relative to consensus, but revenue guidance of $30.1 billion-$30.4 billion remained slightly below analysts’ $30.5 billion estimate, reflecting acquisition and research spending.
• Negative Sentiment: The company posted a $6.75-per-share quarterly loss versus $2.01 of earnings a year earlier. Acquisition-related charges and research-and-development costs overshadowed the operating improvement and raised concerns about deeper 2026 losses. Gilead Second-Quarter Sales Rise
• Negative Sentiment: Veklury sales fell 81% in the quarter, prompting Gilead to lower its full-year outlook for the COVID-19 treatment and highlighting pressure from a declining product. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: AIDS Healthcare Foundation criticized Gilead’s HIV pricing and licensing policies, creating potential reputational and access-related risks in global markets. RBC maintained a Sector Perform rating with a $123 target, below the current valuation.
• Negative Sentiment: CEO Daniel O’Day sold 15,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction is a limited signal because it was scheduled in advance, but it may add to investor caution.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $131.76 on Thursday. The company has a market capitalization of $163.59 billion, a P/E ratio of -49.35 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The firm’s 50 day simple moving average is $129.54 and its two-hundred day simple moving average is $136.18. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 1.86%. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the prior year, the company posted $2.01 earnings per share. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Citigroup lifted their price objective on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Wednesday. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Finally, The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.